Data updated: Mar 10, 2026
DUTREBIS
LAMIVUDINE
Approved 2015-02-06
1
Indication
--
Phase 3 Trials
11
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2015-02-06
- Routes
- ORAL
- Dosage Forms
- TABLET
DUTREBIS Approval History
Loading approval history...
What DUTREBIS Treats
1 FDA approvalsOriginally approved for its first indication in 2015 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DUTREBIS FDA Label Details
ProDUTREBIS Patents & Exclusivity
Latest Patent: Sep 2029
Patents (2 active)
US7754731*PED
Expires Sep 11, 2029
US7754731
Expires Mar 11, 2029
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.